Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Dec 29, 2022 8:03pm
129 Views
Post# 35196305

RE:RE:RE:RE:RE:RE:RE:RE:RE:Last day for tax-loss selling is today!

RE:RE:RE:RE:RE:RE:RE:RE:RE:Last day for tax-loss selling is today!Fabry?

pof, the four Chiesi LSDs are secret. You have no proof that one of them is Fabry. It's a good guess, but unless Bioasis told you, you don't know. Further, there is no public evidence that Chiesi is working with Protalix on any of the four LSDs.

About clinical trials, PRX-102 completed Phase I/II in 2015 and was in Phase III trials at least 3 years before the Chiesi deal. As a matter of fact, interim results of the first 12 months of the BRIDGE trial were released months before the Chiesi deal.

Chiesi and Protalix know full well what the value of Fabry is to them. Bioasis ought to have known. If they didn't know the value then they're incompetent. If they did know and because they sold four LSDs for $3 million, there is no excuse. Either they were asleep, incompatent, or they had somebody else's interests in mind when they made such a deal. It's embarrassing.

So, you can tell us. Do you know if Fabry is one of the four? 

And why are you talking about xB3-Hunter having such high value? Has Bioasis ever even built the xB3-I2S fusion protein? We know they haven't come close to an IND application for it. Why are you and Bioasis placing such a high value on it?

And yet you want to talk down the value of PRX-102, a drug that HAS COMPLETED PHASE III.

You're engaging falsehoods, false evidence, fale claims, false comparisons.

You sound just like Bioasis!!

Why is that, pof?

jd
<< Previous
Bullboard Posts
Next >>